Contact
searchSearch
HMP Global
Login

News

Javier Pinilla Ibarz, MD, PhD
Videos
Evolving Role of CAR-T and Bispecific Therapies in Chronic Lymphocytic Leukemia
04/21/2026
Javier Pinilla-Ibarz, MD, PhD
Javier Pinilla Ibarz, MD, PhD, discusses the evolving role of CAR T-cell therapy and bispecific antibodies in chronic lymphocytic leukemia.
Javier Pinilla Ibarz, MD, PhD, discusses the evolving role of CAR T-cell therapy and bispecific antibodies in chronic lymphocytic leukemia.
Javier Pinilla Ibarz, MD, PhD,...
04/21/2026
Oncology
Justin Taylor, MD
Videos
Next-Generation BTK Degraders for Patients With Chronic Lymphocytic Leukemia
04/21/2026
Justin Taylor, MD
Justin Taylor, MD, discusses the emerging role of Bruton's tyrosine kinase degrader therapies in chronic lymphocytic leukemia.
Justin Taylor, MD, discusses the emerging role of Bruton's tyrosine kinase degrader therapies in chronic lymphocytic leukemia.
Justin Taylor, MD, discusses the...
04/21/2026
Oncology
Jennifer Brown, MD, PhD
Videos
Bruton's Tyrosine Kinase Inhibitor Resistance and Treatment Sequencing in Chronic Lymphocytic Leukemia
04/13/2026
Jennifer Brown, MD, PhD
Jennifer Brown, MD, PhD, discusses mechanisms of resistance to BTKi in chronic lymphocytic leukemia, including mutations associated with both covalent and non-covalent agents.
Jennifer Brown, MD, PhD, discusses mechanisms of resistance to BTKi in chronic lymphocytic leukemia, including mutations associated with both covalent and non-covalent agents.
Jennifer Brown, MD, PhD,...
04/13/2026
Oncology
Erin Mulvey, MD
Videos
Advances in Targeted and Immunotherapy for Richter Transformation
04/10/2026
Erin Mulvey, MD
At the 2026 LL&M Winter Symposium, Erin Mulvey, MD, discusses the evolving treatment landscape for Richter transformation.
At the 2026 LL&M Winter Symposium, Erin Mulvey, MD, discusses the evolving treatment landscape for Richter transformation.
At the 2026 LL&M Winter...
04/10/2026
Oncology
Richard Furman, MD
Videos
Immature Data Limit Conclusions on Continuous vs Fixed-Duration Frontline CLL Therapies
03/19/2026
Richard Furman, MD
Richard Furman, MD, discusses early results from the CLL-17 trial, underscoring the need for longer follow-up before defining optimal frontline strategies for treatment-naïve patients with chronic lymphocytic leukemia.
Richard Furman, MD, discusses early results from the CLL-17 trial, underscoring the need for longer follow-up before defining optimal frontline strategies for treatment-naïve patients with chronic lymphocytic leukemia.
Richard Furman, MD, discusses...
03/19/2026
Oncology
FDA Approval
FDA Approves Acalabrutinib Plus Venetoclax for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
02/20/2026
Emily Estrada
Based on results from the phase 3 AMPLIFY trial, the FDA has approved acalabrutinib plus venetoclax for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Based on results from the phase 3 AMPLIFY trial, the FDA has approved acalabrutinib plus venetoclax for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Based on results from the phase...
02/20/2026
Oncology
Matthew Davids, MD
Videos
Genetic Risk Factors May Help Predict Richter Transformation in Chronic Lymphocytic Leukemia
01/05/2026
Matthew S. Davids, MD, MMSc
Matthew Davids, MD, highlights advances in identifying and managing Richter transformation among patients with chronic lymphocytic leukemia.
Matthew Davids, MD, highlights advances in identifying and managing Richter transformation among patients with chronic lymphocytic leukemia.
Matthew Davids, MD, highlights...
01/05/2026
Oncology
Wojciech Jurczak, MD, PhD
Conference Coverage
Frontline Pirtobrutinib Shows Superior PFS vs Bendamustine-Rituximab for CLL/SLL: BRUIN CLL-313 Trial
12/15/2025
Wojciech Jurczak, MD, PhD
According to first results from a phase 3 trial presented by Wojciech Jurczak, MD, PhD, at the 2025 ASH Annual Meeting, pirtobrutinib showed superior PFS and tolerability for treatment-naïve chronic lymphocytic leukemia/small lymphocytic...
According to first results from a phase 3 trial presented by Wojciech Jurczak, MD, PhD, at the 2025 ASH Annual Meeting, pirtobrutinib showed superior PFS and tolerability for treatment-naïve chronic lymphocytic leukemia/small lymphocytic...
According to first results from...
12/15/2025
Oncology
Catherine Coombs, MD
Conference Coverage
Evolving Treatment Strategies for Patients With Chronic Lymphocytic Leukemia
06/28/2025
Catherine Coombs, MD
At the 2025 Great Debates in Hematologic Malignancies meeting , Catherine Coombs, MD, discussed insights into evolving treatment strategies for patients with chronic lymphocytic leukemia.
At the 2025 Great Debates in Hematologic Malignancies meeting , Catherine Coombs, MD, discussed insights into evolving treatment strategies for patients with chronic lymphocytic leukemia.
At the 2025 Great Debates in...
06/28/2025
Oncology
Catherine Coombs, MD
Conference Coverage
Evolving Treatment Strategies for Patients With Chronic Lymphocytic Leukemia
06/28/2025
Catherine Coombs, MD
At the 2025 Great Debates in Hematologic Malignancies meeting , Catherine Coombs, MD, discussed insights into evolving treatment strategies for patients with chronic lymphocytic leukemia.
At the 2025 Great Debates in Hematologic Malignancies meeting , Catherine Coombs, MD, discussed insights into evolving treatment strategies for patients with chronic lymphocytic leukemia.
At the 2025 Great Debates in...
06/28/2025
Oncology

Recent News

FDA Alerts
Capivasertib Gains Support from the FDA’s Advisory Committee in Metastatic Hormone-Sensitive Prostate Cancer
05/04/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase...
05/04/2026
Oncology
FDA Approval
FDA Approves Vepdegestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
05/01/2026
Emily Estrada
Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Based on results from the phase...
05/01/2026
Oncology
News
Varegacestat Advances Toward FDA Review in Desmoid Tumors
04/30/2026
Stephanie Holland
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Based on results from the phase...
04/30/2026
Oncology
News
Nirogacestat Improves Outcomes Across Prognostic Subgroups of Patients With Desmoid Tumors
04/30/2026
Stephanie Holland
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Results from a post hoc analysis...
04/30/2026
Oncology
News
FOG-001 Shows Early Activity in Patients With Desmoid Tumors
04/30/2026
Stephanie Holland
Results from a phase 1/2 study demonstrate that FOG-001 shows early clinical activity with manageable safety in patients with desmoid tumors.
Results from a phase 1/2 study demonstrate that FOG-001 shows early clinical activity with manageable safety in patients with desmoid tumors.
Results from a phase 1/2 study...
04/30/2026
Oncology
News
Bireociclib Plus Fulvestrant in HR-Positive, HER2-Negative Advanced Breast Cancer
04/30/2026
Emily Estrada
Final results from the phase 3 BRIGHT-2 trial demonstrated that bireociclib plus fulvestrant significantly improves PFS compared with fulvestrant alone in previously treated HR-positive, HER2-negative advanced breast cancer.
Final results from the phase 3 BRIGHT-2 trial demonstrated that bireociclib plus fulvestrant significantly improves PFS compared with fulvestrant alone in previously treated HR-positive, HER2-negative advanced breast cancer.
Final results from the phase 3...
04/30/2026
Oncology
News
Romiplostim Reduces the Need for Dose Modifications in Chemotherapy-Induced Thrombocytopenia
04/30/2026
Emily Estrada
Results from the phase 3 RECITE trial demonstrated that romiplostim significantly reduced the need for chemotherapy dose modifications in patients with chemotherapy-induced thrombocytopenia.
Results from the phase 3 RECITE trial demonstrated that romiplostim significantly reduced the need for chemotherapy dose modifications in patients with chemotherapy-induced thrombocytopenia.
Results from the phase 3 RECITE...
04/30/2026
Oncology
News
Tri-Weekly Cisplatin Matches Weekly Dosing With Better Tolerability in Cervical Cancer
04/30/2026
Stephanie Holland
Results from the phase 3 TACO trial demonstrate that tri-weekly cisplatin provides similar survival with improved safety and quality of life vs weekly dosing in patients with locally advanced cervical cancer.
Results from the phase 3 TACO trial demonstrate that tri-weekly cisplatin provides similar survival with improved safety and quality of life vs weekly dosing in patients with locally advanced cervical cancer.
Results from the phase 3 TACO...
04/30/2026
Oncology
FDA Alerts
FDA Grants Breakthrough Therapy Designation to TERN-701 in Ph-Positive Chronic Myeloid Leukemia
04/30/2026
Stephanie Holland
Based on data from the phase 1/2 CARDINAL study, the FDA has granted breakthrough therapy designation to TERN-701 for previously treated Ph-positive chronic myeloid leukemia.
Based on data from the phase 1/2 CARDINAL study, the FDA has granted breakthrough therapy designation to TERN-701 for previously treated Ph-positive chronic myeloid leukemia.
Based on data from the phase 1/2...
04/30/2026
Oncology
News
HSK42360 Shows Clinical Promise in BRAF V600-Mutant Glioma
04/29/2026
Emily Estrada
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study...
04/29/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use